BioSpace News Archive

Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, reported financial results for the third quarter ended September 30, 2021.

Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the company has dosed the first patient in its phase II clinical trial of pyrilutamide in China for the treatment of androgenetic alopecia female patients.

RELIEF THERAPEUTICS Holding SA reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc., has issued a press release announcing receipt of the U.S. Food and Drug Administration’s response to NRx’s October 8, 2021 submission of updated manufacturing information for aviptadil.

Mirion Technologies, Inc. today announced results for the quarter ended September 30, 2021.

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, announced its financial results for the third quarter ended September 30, 2021 and provided an update on recent corporate developments.

Tempest Therapeutics, Inc. (Nasdaq: TPST), today reported in vitro and in vivo preclinical data demonstrating the potent dual mechanistic activity of TPST-1495, an orally-available small molecule designed to block the EP2 and EP4 receptors in the prostaglandin (PGE2) pathway.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting.

Catalyst Biosciences, Inc. announced a strategic decision to halt the clinical development of MarzAA, report data to date, and seek a buyer for its hemophilia assets.

Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced updated interim data from the Phase 1 data from RP2 alone and in combination with Opdivo that continues to provide strong support for the next stage development of RP2.

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc., announced the pricing of its initial public offering of common stock.